Statement of Changes in Beneficial Ownership (4)
November 02 2022 - 06:30PM
Edgar (US Regulatory)
|
FORM 4
[ ] Check this box if no longer subject to Section
16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
| 1. Name
and Address of Reporting Person * Berger Adam
Mark |
2. Issuer Name and Ticker or Trading
Symbol AMARIN CORP PLCUK [ AMRN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)__X__
Director _____
10% Owner
_____ Officer (give title
below) _____ Other
(specify below)
|
|
(Last)
(First)
(Middle)
C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22 |
3. Date of Earliest Transaction (MM/DD/YYYY)
10/20/2022
|
|
(Street)
BRIDGEWATER, NJ 08807
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
Amount |
(A) or (D) |
Price |
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
|
Stock Option (Right to Buy) |
$1.09 |
10/20/2022 |
|
A |
|
302122.00 |
|
(1) |
10/20/2032 |
Ordinary Shares (2) |
302122.00 |
$0.00 |
302122.00 |
D |
|
|
Restricted Stock Units (3) |
$0.00 |
10/20/2022 |
|
A |
|
247707.00 |
|
(4) |
(5) |
Ordinary Shares (2) |
247707.00 |
$0.00 |
247707.00 |
D |
|
| Explanation of
Responses: |
| (1) |
On October 20, 2022, the
Reporting Person was granted an option to purchase 302,122 Ordinary
Shares under the Amarin Corporation plc 2020 Stock Incentive Plan
(the "Plan"). The option shall vest and become exercisable in a
single annual installment upon the one-year anniversary of the
grant date of October 20, 2022. |
| (2) |
The Ordinary Shares may be
represented by American Depositary Shares, each of which currently
represents one Ordinary Share. |
| (3) |
Each Restricted Stock Unit
("RSU") represents a contingent right to receive one Ordinary Share
or cash in lieu thereof at the Issuer's discretion. |
| (4) |
On October 20, 2022, the
Reporting Person was granted 247,707 RSUs under the Plan. The RSUs
vest in equal annual installments over a three-year period, with
each installment vesting upon the anniversary of the grant date of
October 20, 2022. |
| (5) |
Not applicable. |
Remarks:
These grants are made in accordance with the Issuer's previously
disclosed non-employee director compensation program. In the event
of a Change of Control (as defined in the Plan), each of the grants
described in this Form 4 vests in full. |
Reporting
Owners
|
|
Reporting Owner Name / Address |
Relationships
|
|
Director |
10% Owner |
Officer |
Other |
Berger Adam Mark
C/O AMARIN PHARMA, INC.
440 US HIGHWAY 22
BRIDGEWATER, NJ 08807 |
X |
|
|
|
Signatures
|
|
/s/ Jason Marks, by power of
attorney |
|
11/2/2022 |
| **Signature of
Reporting Person |
Date |
|
Reminder: Report on a separate line for each class
of securities beneficially owned directly or
indirectly. |
| * |
If the form is filed by more than one
reporting person, see Instruction 4(b)(v). |
| ** |
Intentional misstatements or omissions
of facts constitute Federal Criminal Violations. See 18
U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: |
File three copies of this Form, one of
which must be manually signed. If space is insufficient, see
Instruction 6 for procedure. |
|
Persons who respond to the collection of information
contained in this form are not required to respond unless the form
displays a currently valid OMB control number. |
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Feb 2023 to Mar 2023
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2022 to Mar 2023
